Momenta Phamaceuticals, Inc. (NASDAQ: MNTA) reported Q3 EPS of ($0.50), $0.02 worse than the analyst estimate of ($0.48). Revenue for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE